BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:RAY1225 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of RAY1225\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07139548-198@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:RAY1225: Phase 3 readout est. (NCT07139548)
DESCRIPTION:RAY1225\, phase 3\, Type 2 Diabetes.\nStudy: A Study of RAY1225
  Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Partic
 ipants With Type 2 Diabetes\nEstimated primary completion: 1 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ray1225#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07139548
URL:https://assetmemo.bio/drug/ray1225#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139535-198@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:RAY1225: Phase 3 readout est. (NCT07139535)
DESCRIPTION:RAY1225\, phase 3\, Type 2 Diabetes.\nStudy: A Study of RAY1225
  in Participants With Type 2 Diabetes Not Controlled With Diet and Exercis
 e Alone\nEstimated primary completion: 1 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ray1225#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07139535
URL:https://assetmemo.bio/drug/ray1225#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
